Baxter International plans to spin off kidney care units

The company said the restructuring will allow it to "create a more resilient supply chain and greater alignment with the company's manufacturing footprint".

Published On 2023-01-08 09:30 GMT   |   Update On 2023-01-08 09:30 GMT
Advertisement

US: Baxter International Inc said on Friday it plans to spin off its kidney care units, becoming the latest medical device maker to slim down in the face of supply-chain challenges.

The company plans to spin off its renal care and acute therapies units into a separate listed entity in the next 12-18 months. It is also exploring alternatives for its biopharma solutions business, including a potential sale or other separation options.

Advertisement

Dialysis operations, which are a part of Baxter's renal care unit, are a drag on the parent company's margins today, said Chief Financial Officer James Saccaro.

Medical device makers are still grappling with supply-chain shortages that began during the pandemic, with rising costs of raw materials, labor, and transportation piling on more pressure.

Baxter's rival Medtronic said in October it would spin off two of its smaller businesses into a new company to streamline its portfolio and increase the pace of revenue growth.

"Our current operating model, which has served us well previously, does create an element of operational complexity, which became more evident last year when working through the challenges created by the unprecedented volatility in the macro environment," Baxter Chief Executive Officer José Almeida said in a conference call with investors.

Read also: Baxter launches cardiovascular medicine Norepinephrine in premix formulation in US

The company said the restructuring will allow it to "create a more resilient supply chain and greater alignment with the company's manufacturing footprint".

For the nine months ended Sept. 30, the renal care unit reported sales of $2.77 billion, down from $2.87 billion the previous year. The acute therapies unit posted sales of $519 million, declining from $580 million a year ago

Read also: Baxter Pharma India sets up global Pharmaceuticals RnD Centre in Ahmedabad

Tags:    
Article Source : Reuters

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News